Cargando…
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
Autores principales: | Montillo, M, O'Brien, S, Tedeschi, A, Byrd, J C, Dearden, C, Gill, D, Brown, J R, Barrientos, J C, Mulligan, S P, Furman, R R, Cymbalista, F, Plascencia, C, Chang, S, Hsu, E, James, D F, Hillmen, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386339/ https://www.ncbi.nlm.nih.gov/pubmed/28157216 http://dx.doi.org/10.1038/bcj.2017.5 |
Ejemplares similares
-
Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019) -
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
por: Munir, Talha, et al.
Publicado: (2019) -
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
por: Brown, J R, et al.
Publicado: (2018) -
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Barrientos, Jacqueline C., et al.
Publicado: (2018) -
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)